HC Wainwright reissued their buy rating on shares of Invivyd (NASDAQ:IVVD – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $15.00 price objective on the stock.
Invivyd Price Performance
Shares of Invivyd stock opened at $0.91 on Tuesday. The stock has a market capitalization of $108.21 million, a price-to-earnings ratio of -0.48 and a beta of 0.63. The firm’s fifty day simple moving average is $0.99 and its 200-day simple moving average is $1.41. Invivyd has a 12 month low of $0.81 and a 12 month high of $5.20.
Invivyd (NASDAQ:IVVD – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.03). The business had revenue of $2.26 million for the quarter, compared to the consensus estimate of $4.91 million. Analysts anticipate that Invivyd will post -0.6 earnings per share for the current year.
Hedge Funds Weigh In On Invivyd
About Invivyd
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Further Reading
- Five stocks we like better than Invivyd
- Trading Stocks: RSI and Why it’s Useful
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Technology Stocks Explained: Here’s What to Know About Tech
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- How to Invest in Small Cap Stocks
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.